1 Implementation of Point of Care HIV Viral load monitoring

2 for people living with HIV in Low and Middle-income

3 Countries: A systematic review on implementation research

4 outcomes.

- 5 Perry Msoka^{1,2,3}, Iraseni Swai^{1,3,4}, Kennedy Ngowi¹, Ria Reis^{3,5}, Andreja Lekic², Blandina T.
- 6 Mmbaga^{1,6,7}, Anita Hardon^{3,8}, Marion Sumari-de Boer^{1,3,6,8}
- 7

8 Affiliations:

- 9 1. Kilimanjaro Clinical Research Institute, Moshi, Tanzania
- 10 2. Amsterdam Institute for Social Science Research, Amsterdam, the Netherlands
- 11 3. Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands
- 12 4. UMC Amsterdam, location AMC, Amsterdam, the Netherlands
- 13 5. The Children's Institute, University of Cape Town, Cape Town, South Africa
- 14 6. Kilimanjaro Christian Medical University College, Moshi, Tanzania
- 15 7. Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 16 8. Knowledge, Technology and Innovation Chair group, Social Sciences Department,
- 17 Wageningen University & Research, the Netherlands
- 18

| 20 | Corresponding author: Perry Cyril Msoka. Kilimanjaro Clinical Research Institute |
|----|--|
| 21 | Moshi, Kilimanjaro, Tanzania |
| 22 | p.msoka@kcri.ac.tz |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |

34 Abstract

35 Background

Viral load monitoring has rapidly increased among people living with HIV(PLHIV) in low- and 36 37 middle-income countries (LMICs), resulting in an increased laboratory workload. The use of 38 innovative Point of Care (PoC) or near Point of Care (n)PoC HIV Viral Load (HIV VL) monitoring has enabled improved patient care, a reduction in laboratory workload, improved 39 40 clinic retention and reduced turnaround time of results. However, implementation bottlenecks of such methods are uncertain, especially when PoC or (n)PoC is implemented in remote areas in 41 42 low-volume clinics. The main aim of this study was to review implementation research outcomes 43 of (n)PoC HIV VL monitoring for PLHIV in LMICs.

44 Methodology

We qualitatively synthesised peer-reviewed papers to explore implementation research outcomes 45 46 (IROs) of (n)PoC HIV VL monitoring. We identified studies published between January 2013 and June 2024. We used the IROs described by Proctor et al., which are acceptability, adoption, 47 48 appropriateness, cost, feasibility, fidelity, penetration and sustainability. We searched using the following Mesh terms: Point of care testing, HIV, viral load, acceptability, patient acceptance of 49 50 health care, adoption, facilities and services utilisation, appropriateness, cost, feasibility, fidelity, 51 penetration, coverage, sustainability and continuity of patient care through PubMed, Cochrane 52 and Scopus. The PRISMA diagram in Figure 1 presents the selection process of included papers.

53 Results

54 Twenty-five studies reported implementation outcomes of PoC or (n)PoC HIV VL monitoring. Near PoC HIV VL monitoring using GeneXpert is considered acceptable to patients and 55 56 healthcare providers. Point of care HIV VL monitoring using mPIMA was feasible as patients received the results the same day. From a health service provider's perspective, PoC HIV VL 57 58 monitoring was acceptable because it influenced patients to accept the illness and adhere to medication. Additionally, there was high testing coverage in routine PoC HIV VL monitoring 59 60 centres. Fidelity was questionable in some settings due to (n)PoC HIV VL monitoring results not being delivered as intended. Additionally, we found in several studies that the (n)PoC costs are 61 higher than standard of care test, USD 54.93 per test, at low testing volume clinics conducting 62 20VL tests per month compared to costs of USD 24.25 at high testing volume clinics conducting 63

100VL tests per month. However, costs are expected to be lower when (n)PoC HIV VL
monitoring is scaled up and targeted for those at risk.

66 Conclusion

Implementation of PoC or (n)PoC testing for HIV viral load monitoring is acceptable and feasible and can reach a vast population. However, higher costs, limited fidelity, lower penetration and limited sustainability may hinder using (n)PoC testing in improving patient care and health outcomes. More knowledge and training should be implemented to overcome these challenges.

72

- Keywords: Point of Care HIV Viral Load monitoring; People living with HIV; systematic
 review; Implementation research outcomes; Low and middle-income countries
- 76
- 76
- 77
- 78
- 79
- 75
- 80
- 81
- 82
- 83
- 00
- 84
- 85

86 Introduction

Globally, an estimated 39.9 million people were living with Human Immunodeficient Virus
(HIV) in 2023, of whom 77% of adults and 57% of children accessed antiretroviral therapy
(ART).(1) The Joint United Nations Programme on HIV and AIDS (UNAIDS) aims to reach 95-

90 95-95 targets by 2030 that 95% of people living with HIV (PLHIV) know their HIV status, 95%
91 of diagnosed PLHIV receive antiretroviral therapy (ART), and 95% of PLHIV receiving ART
92 attain viral suppression below 1,000 copies/ml.(2) To reach these goals, the World Health
93 Organization (WHO) emphasizes that all PLHIV receive ART and routine HIV viral load (VL)
94 testing to monitor treatment response, adherence and virologic suppression.(3)

However, monitoring the VL of PLHIV on ART in resource-limited settings is still challenging
due to limited infrastructure, shortage of skilled staff, loss of samples, an inefficient system of
providing results and patients being lost to follow-up.(4) To overcome those challenges, WHO
has advocated for integrating Point of care HIV Viral load (PoC HIV VL) monitoring in HIV
care services.(5,6)

Point of Care HIV VL monitoring entails testing at the point where healthcare is provided. The results can be given on the same day. Also, it can usually be performed by non-trained staff.(7) Near Point of Care HIV VL monitoring is testing in laboratories close to treatment facilities, while still improving the turnaround time from sampling to result.(8) The current PoC HIV VL assays that are commercially available or in late development include the PoC HIV assay of mPIMA by Abbott, and the (n)PoC HIV assays SAMBA by Diagnostics for the Real World and GeneXpert HIV 1 by Cepheid.(9)

107 Several studies have been conducted on the performance of PoC HIV VL monitoring. In 108 Mozambique, mPIMA was found to have a high sensitivity of 95% and specificity of 96.5% to 109 identify virological failure at the threshold of 1000 copies/ml when a standard conventional 110 plasma test was used as the golden standard.(10) In addition, a study evaluating the performance 111 of SAMBA in Malawi and Uganda found it to be accurate in differentiating patients who had a 112 VL below or above 1000 copies/ml.(11)

Furthermore, a systematic review study from developed and developing countries found that PoC testing is preferable to centralized testing, with a sensitivity of 93.3%- 100% and specificity of 99.5%- 100% for Early Infant Diagnosis (EID), acute HIV infection diagnosis, or VL monitoring.(12)

Despite the good performance of PoC HIV VL monitoring in previous studies, several challenges
exist. A systematic review of the performance and clinical utility of POC HIV viral load testing

in resource-limited settings observed that there is a need for constant electricity for the machineto function and a temperature control room for sample processing and storage.(12)

121 Other reported challenges of PoC HIV VL monitoring are device operation by untrained staff, 122 routine device maintenance, and the high costs of a PoC test. All these may hamper the 123 implementation of PoC HIV VL monitoring.

124 Given the above-reported challenges, future studies should explore solutions to overcome 125 possible implementation challenges. Proctor and colleagues (2011) designed a framework that 126 describes eight distinct implementation outcomes to guide the successful implementation of innovations: acceptability, adoption, appropriateness, feasibility, fidelity, implementation costs, 127 128 penetration and sustainability. Acceptability is the perception among stakeholders that a given 129 treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. Secondly, 130 adoption is the intention, initial decision, or action to try or employ an innovation or evidencebased practice. Thirdly, appropriateness is the perceived fit of the innovation to address a 131 132 particular issue or problem. Fourthly, the cost is the financial effect of an implementation effort. 133 It may include charges for treatment delivery, implementation strategy and use of the service setting. Fifthly, feasibility is how a new treatment or innovation can be successfully used or 134 carried out within a given agency or setting. Sixthly, fidelity is defined as the extent to which an 135 136 intervention was implemented as prescribed in the original protocol or as the program developers intended. Seventhly, penetration is integrating practice within a service setting and its 137 138 subsystems. Lastly, sustainability is how a newly implemented intervention is maintained or institutionalised within a service setting's ongoing, stable operations. These implementation 139 outcomes can give insights into challenges and assist in developing strategies to be investigated 140 141 in future pragmatic trials.(13)

In this systematic review, we use the Proctor framework to explore implementation research outcomes of (n)PoC HIV VL monitoring for PLHIV in LMICs through a qualitative synthesis of peer-reviewed papers. The specific objectives were to review existing evidence on (1) the acceptability, (2) the adoption, (3) the appropriateness, (4) the cost, (5) the feasibility, (6) the fidelity, (7) the penetration and (8) the sustainability of (n)PoC HIV VL monitoring.

147

148 Methodology

- 149 Using the reporting items in systematic review guideline(14) we qualitatively synthesised
- 150 scientific papers to explore the implementation research outcomes (IROs) of PoC HIV VL
- 151 monitoring for PLHIV. We used the Proctor framework of IROs and pre-defined topics to define
- the search terms.(13)

153 Literature search

- The initial broad relevant MESH terms were defined based on the terms 'PoC testing', 'HIV' and Viral load'. We viewed the proper entry terminology for the IROs: Acceptability, Adoption,
- Appropriateness, Cost, Feasibility, Fidelity, Penetration and Sustainability. After defining these terms, we searched for the terms in June 2024 using a combination of the MESH and entry

- terms. A detailed search strategy is presented in the S1 Table.
- 159 Three databases were searched for publications published between January 2013 and June 2024:
- 160 (1) PubMed, (2) Cochrane and (3) Scopus. After this, we scanned the reference list of each
- 161 obtained publication found through the above search for additional publications that could fit our
- 162 search criteria.

163 Study selection

- 164 Publications were included based on the following criteria:
- Quantitative, including trials or qualitative studies.
- Original papers.
- Focus on (n)PoC VL monitoring.
- A publication should at least describe one of the IROs as described by Proctor.
- 169

170 We used Covidence software https://support.covidence.org/help/how-can-i-cite-covidence to select and organise manuscripts and data extraction. The publications were identified and 171 172 imported with a librarian (A) into the software for selecting eligible publications. After collecting 173 publications from PubMed, Cochrane and Scopus, the titles and abstracts of identified studies were screened by two reviewers (PM, MS) for relevance. Any disagreements during the 174 175 screening of titles and abstracts were resolved through discussion. In case of doubt that a publication met the criteria, it was included for full-text assessment to assess the eligibility. The 176 177 full-text assessment of the quality and risk of bias of all included publications was performed by

| 178 | two reviewers (PM, MS). We used the Newcastle Ottawa scale (NOS) to assess the risk of |
|-----|--|
| 179 | bias. (15) The tool assessed the bias in three categories which are: selection, comparability, and |
| 180 | outcome or exposure. A star system was used: a score of seven to nine stars was considered a |
| 181 | low risk of bias, four to six stars were considered an "unclear risk of bias", and three or fewer |
| 182 | stars were considered a "high risk of bias". The study was considered of low quality if we found |
| 183 | it to have a high risk of bias. |
| 184 | All manuscripts included in the full-text assessment were judged based on the quality of the |
| 185 | paper using twenty-seven criteria selected from the PRISMA guidelines for reporting systematic |
| 186 | reviews.(16) The PRISMA checklist can be found in the S2 Table. The twenty selected criteria |
| 187 | covered the following items: |
| 188 | • The abstract was comprehensive. |
| 189 | • The objective did clearly state the specific aims of the study. |
| 190 | • The rationale was based on a well-described literature review. |
| 191 | • The methodology clearly described qualitative or quantitative methods, research |
| 192 | setting and participants, methods and data collection procedures. |
| 193 | • Ethical issues were assessed by judging informed consent procedures, voluntary |
| 194 | participation, no harm, confidentiality and anonymity. |
| 195 | • The analysis and results had to be realistic to achieve the required study objective. |
| 196 | |
| 197 | Exclusion criteria were: |
| 198 | • Studies with outcomes that were not relevant to our review. |
| 199 | • Studies describing interventions outside of our area of interest. |
| 200 | • Studies and reviews of papers published before 2013 in which PoC VL testing |
| 201 | was not widely available or implemented. |
| 202 | • Protocol studies. |
| 203 | Data extraction and management |
| 204 | One reviewer (PM) extracted the data. The following information was extracted from the |
| 205 | included studies: |
| 206 | Country where the study was performed |

• Country where the study was performed

| 207 | • Study design classified as clinical trials, cohort, qualitative or modelling studies |
|-----|---|
| 208 | • Study funding sources |
| 209 | Population description |
| 210 | • Study period, start and end date |
| 211 | • Inclusion and exclusion criteria |
| 212 | • Methods of recruitment of the participants |
| 213 | • Implementation of research outcomes (IROs) investigated |
| 214 | |
| 215 | Ethical Approval and Informed Consent |
| 216 | The review was registered on the PROSPERO registry for systematic reviews. (PROSPERO |
| 217 | 2023 CRD42023394668). The review did not involve collecting new data from human subjects. |
| 218 | Therefore, ethical approval and informed consent were not required. |
| | |

219

220 **Results**

221 Three hundred and thirteen studies were found through the initial search of PubMed, Scopus and Cochrane, and an additional five studies were found through scanning the reference lists. Forty-222 four duplicate studies were removed from the 318 studies. As a result, 274 studies were screened 223 for eligibility based on title and abstract. From that, 240 irrelevant studies were excluded because 224 225 the publications focused on something other than (n) PoC VL monitoring. Thirty-four studies were assessed on eligibility by reading the full text of the paper. We found that nine studies were 226 227 not eligible: three had irrelevant outcomes for our review, three described interventions outside 228 our area of interest, and three had wrong study designs, as detailed in the S3 Table. This led to 25 229 studies being included in the final review, as shown in Table 1. The PRISMA diagram showing detailed information on search results and the selection process is presented in S1 Figure. 230

- 232
- 233
- 234
- 235
- 236

| 237 | |
|-----|--|
| 237 | |
| | |
| 239 | Study characteristics |
| 240 | Twenty-five papers were included in this systematic review.(17-41)Among the studies, seventeen |
| 241 | were quantitative studies,(18,19,21,22,24–28,30–32,34,36–38,41) six were qualitative |
| 242 | studies,(20,29,33,35,39,40) and two were mixed methods studies.(17,23) |
| 243 | |
| 244 | |
| 245 | |
| 246 | |
| 247 | |
| 248 | |
| 249 | |
| 250 | |
| 251 | |
| 252 | |
| 253 | |
| 254 | |
| 255 | |
| 256 | |
| 257 | |
| 258 | |
| 259 | |
| 260 | |
| 261 | |
| 262 | |
| 263 | |
| 264 | |
| 265 | |
| 266 | |
| 267 | |
| | |

268

| | Study design and setting | Collection | | | OC test Acceptability | | Appropriatenes s | (High/ | Feasibility | Fidelity | Penetration | Sustainability |
|--|---|-------------------------|-----------|-------|--|--|---------------------|--|---|----------|-------------|----------------|
| | | method | nPoC | PoC | | | | low) | | | | |
| 3oyce et al. (2023) Uganda | Open-label, pilot study in lower-level health centre in rural Uganda | Quantitative | GeneXpert | | | | | | (n)PoC test was more successful than centralized testing due to a reduction in time to results | | | |
| Reif et al. (2022) Haiti | Randomized control trials included HIV AIDS clinic | Quantitative method | GeneXpert | | The majority of patients receive results the same day and immediate counselling | | | | | | | |
| Tembo et al. (2022) Lusaka, Zambia | Purposive sampling included six health facilities | Qualitative met ho d | | mPIMA | Patients were influenced to accept the illness and adhere to medication | | | Low costs of PoC test as the test was done on the spot | | | | |

| Author/Year/ Country | Study design and setting | Collection | Type of PO | C test | Acceptability | Adoption | Appropriatenes s | (High/ | Feasibility | Fidelity | tes be | Sustainability |
|---|--|--------------|------------|--------|---------------|----------|---|---|--|----------|-----------|--|
| | | method | nPoC | PoC | - | | | low) | | | | |
| Boeke et al. (2021) Cameroon, Congo, Senegal, Kenya, Tanzania, Zimbabwe, Malawi | Retrospective Study included 57 Public- sector health facilities | Quantitative | GeneXpert | mPIMA | | | High perceived fit of PoC VL monitoring results available at the PoC or (n)PoC | | | | | PoC or (n)PoC test program to be maintained, there is a need for clear protocol diagnostic pathways |
| Bulteryrs et al (2021) Kenya | Observation study included five Ministry of Health Facilities | | GeneXpert | | | | | High (n)PoC test Costs USD 54.93 in low- volume clinics and a low-cost USD 24.25 in high- volume clinics | Low feasibility in some settings that shared the same instrument caused delays in VL results | | | there is a need for clear protocol diagnostic pathways |

| It is made available under a CC-BY 4.0 International license. | (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. | medRxiv preprint doi: https://doi.org/10.1101/2024.11.04.24316630; this version posted November 5, 2024. The copyright holder for this preprint |
|---|---|---|
|---|---|---|

| Author/Year/ Country | Study design and setting | Data Collection | Type of PO | C test | Acceptability | Adoption | (High/ | Feasibility | Fidelity | Penetration | Sustainability |
|--|--|---|---------------|--------|--|---|--------|---|----------|--|--|
| | | method | nPoC | PoC | | | low) | | | | |
| - | Cohort study included four HC, one DH, one RH | Quantitative | SAMBA 1 VL | | | Turnaround time within a short period from blood draw to results was reduced | | (n)PoC test was more successful than centralized testing | | Manpower insufficient and high workload | (n)PoC test in clinics with challenges of staff availability |
| Sharma et al. (2021) South Africa | Randomized control trials included large public clinic | Quantitative method | GeneXpert | | The majority of patients receive results the same day and immediate counselling | | | | | | and power (n)PoC test increased in healthcare settings, providing adequate care according to patient needs |
| Wang et al. (2022) Malawi and Zimbabwe | Quantitative study in 18 health facilities | Clinic register and patient charts | GeneXpert | | | | | Multidisea se tool was highly feasible to scale up HIV testing | | | |

| Author/Year/ Country | Study design and setting | Data Collection | Type of PO | C test | Acceptability | Adoption | Appropriatenes s | (High/ | Feasibility | Fidelity | Penetration | Sustainability |
|---|--|------------------------|------------|--------|---------------|----------|---------------------|---|---|----------|-------------|----------------|
| | | method | nPoC | PoC | | | | low) | | | | |
| Broucker et al. (2021) Southern Zambia | Cohort study included healthcare facilities in Southern Zambia | Quantitative | GeneXpert | mPIMA | | | | Low costs in PoC or (n)PoC test including the test to confirm treatme nt failure and shifting to second- line ART regimen | 2 | | | |
| Ganesh et al. (2021) Malawi | Observation study included two large health facilities | Quantitative method | GeneXpert | | | | | | (n)PoC test was more successful than centralized testing | | | |

| Author/Year/ Country | setting | Collection | Type of POC test | | Acceptability Adoption | | (High/ | Feasibility | Fidelity | Penetration | Sustainability |
|---|--|------------------------|------------------|-------|---|--|--------|--|----------|---|----------------|
| | | method | nPoC | ΡοϹ | | | low) | | | | |
| Villa et al.(2020) Ghana | Prospective pilot study included large hospitals | Quantitative | GeneXpert | | Same-day result reduces drug resistance | | | | | | |
| Drain et al. (2020) South Africa | | Quantitative method | GeneXpert | mPIMA | PoC or (n)PoC test improves HIV care and increases ART adherence monitoring | | | PoC or (n)PoC test shows no delays in diagnosis and sufficient manpower | | | |
| Kufa et al. (2020) South Africa | Prospective Feasibility included four tertiary obstetric units | Qualitative method | GeneXpert | mPIMA | | | | Multidisea se tool was highly feasible to scale up HIV testing | | Nurses are supported in managing stable patients through guidelines | |
| Msimango et al. (2020) South Africa | Randomized control trial included research clinic | | GeneXpert | | (n)PoC test minimised the frequency of clinic visits for high-risk patients | Low appropriatenes s of (n)PoC test in public health facilities with large numbers of people | | | | | |

| | Study design and setting | Data Collection | Type of POC test | | Acceptability | Adoption | Appropriatenes s | 5 Cost (High/ | Feasibility | Fidelity | Penetration | Sustainability |
|------------|--|-------------------------------|------------------|-------|---------------|---|---|---|---|----------|-------------|--|
| | | method | nPoC | ΡοϹ | | | | low) | | | | |
| | Quantitative study included all facilities | Geospatial cost outcome | GeneXpert | mPIMA | | | | Low costs of PoC test to confirm treatme nt failure | | | | Sustainability Low sustainability o (n)PoC test in clinics with several challenges of staff availability and power supply |
| | Quantitative study included hospitals | Quantitative method | | mPIMA | | | | | High feasibility of PoC due to collection of the low volume of plasma by fingerstick in sites without laboratory infrastruct ure | | | |
| al. (2019) | Quantitative study included remote healthcare facilities | Geospatial method | GeneXpert | | | (n)PoC test is adopted well since it is used for multi- disease testing | (n)PoC test produced results immediately | | | | | |

| Author/Year/ Country | Study design and setting | Collection | Type of POC test | | Acceptability Adoption | | Cost (High/ | Feasibility | Fidelity | Penetration | Sustainability | |
|---|---|------------------------|------------------|-------|---|---|---|--|----------|-------------|----------------|--|
| | | method | nPoC | ΡοϹ | | | | low) | | | | |
| Simeon et al. (2019) South Africa | Randomized control trial included research and urban government clinic | | GeneXpert | mPIMA | | | | Low costs of PoC test in high testing volume clinics | | | | |
| | | Quantitative method | SAMBA 1 VL | | (n)PoC test improved HIV care and reduced loss of follow-up | | | | | | | |
| De Necker et al. (2019) Kenya | | Quantitative method | GeneXpert | | | | | Low costs of (n)PoC test in monitori ng treatme nt failure | | | | |
| Ndlovu et al. (2018) Zimbabwe | | Quantitative method | GeneXpert | | | Multi- disease testing increases system efficiency | appropriate for multi-disease testing | High costs of (n)PoC fail to manage samples in some clinics | | | | |
| 296 | | <u></u> | <u></u> | 1 | | | | ll. | 1 | 1 | I | |
| 297 | | | | | | | | | | | | |

| Author/Year/ Country | Study design and setting | Data Collection | Type of POC test | | Acceptability | Adoption | Appropriatenes s | (High/ | Feasibility | Fidelity | Penetration | Sustainability |
|---|--|-----------------------|------------------|-----|--|---|---------------------|-----------------------|--|--|--|---|
| | | method | (n)PoC | PoC | | | | low) | | | | |
| Rasti et al. (2017) Western Uganda | Qualitative study included HC, regional and referral hospital | By Phone | GeneXpert | | (n)PoC test improves the rapid treatment of patients after they receive results | interpreting | | | has been | well due to distrust in test accuracy/lack | | Low sustainability in clinic with poor documentation of results |
| Engel et al. (2017) South Africa | Purposive sampling included home, community, clinic, peripheral lab, hospital, a diagnostic company | Qualitative method | GeneXpert | | Non- laboratory healthcare workers conducted the (n)PoC test | | | | | (n)PoC test was observed that HCWs were not aware and familiar with the guideline | | Low sustainability of (n)PoC test in clinics with several challenges of staff availability and power supply |
| Engel et al. (2015) South Africa | Purposive sampling in two urban and one rural setting | Qualitative method | GeneXpert | | Patient adheres to medication. Multi-disease test evaluates multiple health conditions | Immediate provision of results and counselling to a patient | | test. The test was | No delays in diagnosis and sufficient staffing to run the (n)PoC test | | Nurses are supported in managing stable patients through guidelines. Manpower insufficient | |

| Author/Year/ Country | Study design and setting | Data Collection | Type of POC test | | Acceptability | Adoption | Appropriatenes s | Cost (High/ | Feasibility | Fidelity | Penetration | Sustainability |
|---|--|--------------------|------------------|-----|------------------------------------|----------|---------------------|---|-------------|----------|-------------|---|
| | | method | (n)PoC | PoC | | | | low) | | | | |
| Estill et al. (2013) South Africa | Mathematical Modelling included township ART programs | Quantitative | e GeneXpert | | | | | Low costs in (n)PoC test included the test to confirm treatme nt failure and shifting to second- line ART | | | | Sustainable when (n)PoC test costs are lowered |
| | oC describes near poin | | | | DH describes d | | | regimen s | | | | |
| | C VL describes point of C describes health Cent | | ŀ | | RH describes re ART describes A | | | | | | | |

305

306 Overall results

- 307 We assessed the risk of bias with the Newcastle Ottawa Scale.(15) Fourteen studies had a low
- risk of bias (scored 7-9).(17,18,21–25,28–32,35,38) while ten studies had an unclear risk of bias
- 309 (scored 4-6).(19,20,26,27,33,34,36,37,39,40) Only one study had a high risk of bias and scored
- 310 3; this was the prospective feasibility study conducted in Zimbabwe that highlighted potential
- bottlenecks.(41). The Newcastle Ottawa Scale completed in detail is available in the S4 Table.
- Each study described at least one of the eight IROs defined by Proctor et al.(13)
- 313

314 Acceptability

- Ten studies described the acceptability of (n)PoC VL monitoring.(18–21,25,29,33,35,38,40)
- A study in Malawi, Uganda and South Africa (SA) on SAMBA I HIV, reported high satisfaction
- 317 with (n)PoC VL monitoring, reduced turnaround times from blood draw to results and at the
- same time minimizing clinic visits for high-risk patients.(38,40) Further, in the STREAM study
- in SA, a retrospective cohort study on SAMBA 1 VL in Malawi, and a qualitative study in
- 320 Southwestern Uganda, PoC or (n)PoC VL monitoring was highly acceptable to patients as it
- improves HIV care and ART adherence monitoring.(18–20)
- In addition, studies conducted in Ghana and Haiti using GeneXpert showed that (n)PoC VL monitoring was highly acceptable to patients with the added benefit of results on the same day, reduced drug resistance and immediate counselling.(21,25) Likewise, a qualitative study in SA and Zambia showed that (n)PoC or PoC VL monitoring was highly acceptable by health providers as it helps patients to accept their illness and adhere to medication.(29,33) However, low acceptability of (n)PoC VL monitoring was observed in the SA studies as nonlaboratory healthcare workers conducted (n)PoC tests.(29,35)
- 329
- 330 Adoption
- Four studies described the adoption of (n)PoC VL monitoring.(20,29,30,41)
- 332 Medical professionals and patients observed a high uptake of (n)PoC VL monitoring in studies
- conducted in SA, Kenya and Zimbabwe for its immediate provision of results and counselling to
- patients, including multi-disease testing, which increases system efficiency.(29,30,41) However,

- in a qualitative study conducted in Southwestern Uganda, health staff observed low adoption of
- (n)PoC VL monitoring, coupled with limited knowledge regarding interpreting the results.(20)
- 337
- 338 Appropriateness
- Appropriateness was touched upon in four studies.(30,32,40,41)
- 340 A retrospective study in seven Sub-Saharan countries and the STREAM study in SA showed
- high appropriateness of (n)PoC VL monitoring as results were available at the near point of care.(32,40)
- In addition, a quantitative study in Kenya and the prospective feasibility study conducted in Zimbabwe revealed that (n)PoC testing with GeneXpert was highly appropriate for multi-disease testing as it provides immediate results(30,41) On the contrary, the second qualitative study done in SA observed a low appropriateness of (n)PoC VL monitoring in public health facilities with
- 347 large numbers of people.(40)
- 348
- 349 Costs
- Costs were described in nine studies.(17,23,27–29,31,33,36,41)

An observational study of (n)PoC VL monitoring conducted in Kenya revealed high costs in low-testing volume clinics.(17) Researchers compared the (n)PoC costs with centralised testing, which were 54.93 USD per test and 25.65 USD per test respectively. The costs include personal time for a blood draw, clinical supplies, lab processing, training, lab equipment, electricity, rental space and cartridges. Furthermore, the feasibility study in Zimbabwe showed that (n)PoC VL monitoring had high costs due to failure to manage samples in some clinics.(41)

A cohort study in SA and Zambia and quantitative studies in Kenya observed low costs of PoC VL monitoring that included both the confirmation of treatment failure and the transition to second-line ART regimens.(27,28,31,36) Also, qualitative studies in SA and Zambia showed low costs of PoC tests, as it was performed on the same day and on the spot.(29,33) In addition, a mixed method study in SA showed low costs of (n)PoC VL monitoring in high testing volume clinics.(23)

363

364 Feasibility

365 Feasibility was described in ten studies.(17,18,20,24,26,29,34,37–39)

The SAMBA and feasibility studies in Malawi and Uganda using GeneXpert found that (n)PoC

VL monitoring was more successful due to a reduction in time to results than centralised testing.(34,37,38)

Similarly, a prospective study on the implementation of PoC maternal VL and Early infant diagnosis conducted in SA and the feasibility study in Malawi and Zimbabwe showed that GeneXpert used as a multi-disease testing tool, was highly feasible to scale up HIV testing.(26,39) Furthermore, the STREAM and the qualitative studies in SA and Southwestern Uganda found high feasibility of (n)PoC VL monitoring, enabling rapid diagnosis, which, when coupled with sufficient staffing, contributes to the improvement of healthcare.(18,20,29)

Similarly, the quantitative study on developing and validating a simple and rapid way to generate a low volume of plasma used in PoC VL technology observed high feasibility in sites without laboratory Infrastructure.(24) However, low feasibility was observed in the Kenyan observational study in some settings that shared the same instrument, causing delays in VL results.(17)

380

381 Fidelity

Fidelity was described in three studies. (20,26,35)

The qualitative study in Southwestern Uganda and the feasibility study in Malawi and Zimbabwe revealed that (n)PoC VL monitoring was not implemented accurately. This was due to clients' distrust in the accuracy of the tests and insufficient training for HCWs.(20,26) Also, the qualitative study in SA showed a low fidelity of (n)PoC VL monitoring as HCWs were not aware or familiar with the guidelines.(35)

388

389 Penetration

390 Three studies reported penetration.(29,38,39)

The qualitative, prospective studies in SA reported high penetration of PoC or (n)PoC services when nurses are supported in managing stable patients through guidelines.(29,39) On the contrary, a qualitative study in SA and the SAMBA study in Malawi and Uganda observed low

penetration of the (n)PoC VL monitoring programme due to insufficient manpower and a high

395 workload.(29,38)

396

397 Sustainability

Sustainability was described in six studies. (20,22,32,35,36,38)

A retrospective study in Sub-Saharan African countries, STREAM and cost-effective studies in SA observed high sustainability of PoC or (n)PoC VL monitoring, by having clear diagnostic pathways in healthcare settings, ensuring increased utilisation and adequate patient care, especially when lowering PoC test costs.(22,32,36)

On the other hand, the qualitative studies in Southwestern Uganda and SA and SAMBA studies
in Malawi and Uganda observed low sustainability of (n)PoC VL monitoring in clinics, which is
attributed to poor documentation of results, staff availability challenges and power
supply.(20,35,38)

407

408

409 **Discussion**

This review has accumulated valuable insights into how PoC VL monitoring was implemented in various settings in LMICs and how specific implementation bottlenecks may limit proper implementation. Out of the twenty-five studies, fifteen studies specifically used GeneXpert for (n)PoC VL monitoring, six studies employed both GeneXpert and mPIMA, two studies used SAMBA 1 VL and only two studies focused on mPIMA PoC VL monitoring.

The implementation outcomes of (n)PoC VL monitoring have been widely positive in most of the studies, with reported high satisfaction among patients and HCWs. The benefits reported include reduced turnaround time, minimised clinic visits for high-risk patients, improved HIV care and increased adherence monitoring to antiretroviral therapy (ART), which significantly contribute to the acceptance and uptake of (n)PoC VL monitoring.

The short turnaround time of (n)PoC VL monitoring, providing same-day results was a key factor in its high acceptability. This led to early detection of treatment failure, minimised clinic visits, improved patient outcomes and minimised drug resistance. This was observed in a study conducted by Msimango et al., that (n)PoC VL monitoring was preferred and satisfactory over central laboratory testing as it reduced the frequency of clinic visits. (41)

This review shows that (n)PoC VL monitoring has improved the quality of HIV care from the patient's perspective. Additionally, a study by Nicholas et al., with SAMBA 1 VL test, showed that the same-day VL load test results improved HIV care and reduced follow-up loss.(19)

428 Moreover, PoC or (n)PoC VL monitoring has shown to lead to increased adherence monitoring

to ART. This was evident from a study in South Africa by Drain et al., in which patients

430 highlighted the advantages of MPIMA PoC or GeneXpert (n)PoC VL monitoring and that it

- 431 enhances the monitoring of adherence to Antiretroviral Treatment (ART).(18)
- However, the adoption of PoC VL monitoring in various studies has been hindered by several

433 implementation bottlenecks. Challenges include issues related to non-laboratory HCWs not

knowing how to interpret the results well, making it difficult to integrate (n)PoC VL monitoring
into healthcare practices. This was also noted in a study by Wang et al., where HCWs lacked

436 training to implement (n)PoC VL monitoring tests effectively.(26)

Challenges also arose in terms of appropriateness in public health facilities, with large patient
volumes leading to delays in clinic flow. According to a study by Msimango et al., challenges
arose for the client, as (n)PoC tests may cause delays in clinic flow due to a high number of
people in the facility.(40)

- Costs emerged as a barrier, particularly in low-volume clinics due to the high costs of (n)PoC VL
 monitoring. The study by Simeon et al., noted that (n)PoC VL monitoring reduced its costs in
 low-volume clinics when used for other disease testing as well. (23)
- However, the complexity of multi-disease testing was identified as a challenge too in the review
 studies. This was also reported by Bulterys et al., indicating that clinics with multi-disease
 testing for (n)PoC VL monitoring using GeneXpert are accompanied by several challenges,
 including multiple patient queues causing delays in results and extended clinic visits.(17)

Implementation of (n)PoC VL monitoring challenges including test accuracy, were identified.
Research by Rasti et al., found that patients were concerned about the diagnostic accuracy of
(n)PoC VL monitoring.(20)

- 451 Insufficient manpower and high workloads were recognised as obstacles. Engel et al. reported
- 452 that nurses perceived (n)PoC implementation as an extra workload, leading to patients' delays in
- 453 waiting for the results.(29)

To overcome these implementation bottlenecks, clear diagnostic pathways and proper documentation of results were identified as essential measures to ensure the successful implementation of PoC or (n)PoC VL monitoring.

457 Also, studies showed that (n)PoC VL monitoring was acceptable and well adopted by patients 458 and HCWs due to multi-disease testing and delivery of same-day results.(21,30) On the other

459 hand, PoC VL monitoring was shown to be cost-effective, appropriate and feasible when

- 460 conducted at the point of care.(24,32,33)
- 461 This review has several limitations. The author considered only peer-reviewed published articles,
- did not include unpublished reviews and the period for the included studies was restricted.

463 Studies published between 2013-2024 and limited databases were covered. The lack of data from

464 geographic regions outside of low- and middle-income countries raises a concern about bias and

the generalizability of the findings.

The strength of this review is that we used the Proctor framework, which gives a comprehensive overview of implementation research outcomes. Gaps could suggest further research that can provide better insights into using PoC or (n)PoC VL monitoring in healthcare settings, human

- resources, continuous staff training and sustainable supply chain of PoC or (n)PoC facilities.
- 470

471 Recommendations

Point of Care VL monitoring provides rapid results followed by adherence counselling compared to nPoC VL monitoring. Rapid results provided by PoC VL monitoring improved its acceptability, leading to early detection of treatment failure, minimized clinic visits and improved patient outcomes. To address the implementation challenges of (n)PoC VL monitoring, prioritisation of clear diagnostic pathways and proper documentation are needed, as identified in this review. Further research should address gaps in healthcare settings, human resources, staff training and the sustainable supply chain for facilities that use (n)PoC tests.

479

480 **Conclusion**

Implementing PoC or (n)PoC testing for HIV VL monitoring was acceptable, feasible and can reach a broad population. However, high costs, limited fidelity, and lack of penetration and sustainability may hinder the use of the (n)PoC test in improving patient care and health

outcomes. Our findings indicate different implementation bottlenecks, such as non-laboratory
HCWs not knowing how to interpret results and clinic delays due to high patient volumes.
Additional challenges include increased costs due to low attendance, complex multi-disease
testing and test accuracy concerns. Insufficient manpower and high workloads also affect
implementation.

Point of care knowledge and training are needed to address problems related to implementation
outcomes. This enables researchers, public health communities and policymakers to collaborate
effectively in developing and testing evidence-based interventions.

- 492
- 493
- 494

495 **Acknowledgements**

The authors thank the members of the EAPOC-VL study. The study is a collaboration between 496 497 Uganda National Health Research Organisation/Uganda Virus Research Institute 498 (UNHRO/UVRI, Uganda), Karolinska Institute (Sweden), The Good Samaritan Foundation 499 Kilimanjaro Christian Medical Centre (GSF KCMC, Tanzania), Stichting Amsterdam Institute 500 for Global Health and Development (AIGHD, the Netherlands), London School of Hygiene and 501 Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit, Uganda), National Institute 502 for Medical Research (NIMR, Tanzania), Kenya Medical Research Institute (KEMRI), Center for Global Health Research (CGHR), and the University of Rwanda (UR, Rwanda). 503

- 505
- 506
- 507
- 508
- 509
- 510
- 511
- ---
- 512
- 513

514

515 **References**

- Joint United Nations Programme on HIV/AIDS (UNAIDS) 2024. Fact sheet 2024 Latest global and regional HIV statistics on the status of the AIDS epidemic. 2024; Available from: https://www.unaids.org/en
- Lebelonyane R, Bachanas P, Block L, Ussery F, Alwano MG, Marukutira T, et al. To achieve 95-95 95 targets we must reach men and youth: High level of knowledge of HIV status, ART coverage,
 and viral suppression in the Botswana Combination Prevention Project through universal test and
 treat approach. PLoS One. 2021 Aug 1;16(8 August).
- 5233.Carmona S, Peter T, Berrie L. HIV viral load scale-up: Multiple interventions to meet the HIV524treatment cascade. Vol. 12, Current Opinion in HIV and AIDS. Lippincott Williams and Wilkins;5252017. p. 157–64.
- 5264.Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors Associated527with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in528Uganda, August 2014-July 2015. BMC Infect Dis. 2017 May 3;17(1).
- 5295.Considerations for adoption and use of multidisease testing devices in integrated laboratory530networks: information note. CCBY-NC-SA 30 IGO licence [Internet]. 2017;(June). Available from:531hhtps://iris.who.int/handle/10665/255693
- 5326.Meeting Report. MOLECULAR DIAGNOSTICS INTEGRATION GLOBAL MEETING REPORT. African533Soc Lab Med [Internet]. 2019;(10-12 JULY). Available from: http://apps.who.int/iris
- 5347.Vojnov L, Taegtmeyer M, Boeke C, Markby J, Harris L, Doherty M, et al. Performance of non-535laboratory staff for diagnostic testing and specimen collection in HIV programs: A systematic536review and meta-analysis. Vol. 14, PLoS ONE. Public Library of Science; 2019.
- 5378.Tun NN, Smithuis F, Tun NL, Min M, Hlaing MMM, van Olmen J, et al. Near point-of-care HIV viral538load testing: Cascade after high viral load in suburban Yangon, Myanmar. PLoS One. 2023 Apr5391;18(4 April).
- 5409.Drain PK, Dorward J, Bender A, Lillis L, Marinucci F, Sacks J, et al. Point-of-Care HIV Viral Load541Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response [Internet]. 2019. Available542from: https://journals.asm.org/journal/cmr
- 54310.Meggi B, Bollinger T, Zitha A, Mudenyanga C, Vubil A, Mutsaka D, et al. Performance of a True544Point-of-Care Assay for HIV-1/2 Viral Load Measurement at Antenatal and Postpartum Services545[Internet]. IMPLEMENTATION SCIENCE. 2021. Available from: www.jaids.com
- 54611.Ritchie A V., Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, et al. SAMBA HIV547semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited548settings. J Clin Microbiol. 2014;52(9):3377–83.
- 54912.Agutu CA, Ngetsa CJ, Price MA, Rinke de Wit TF, Omosa-Manyonyi G, Sanders EJ, et al. Systematic550review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and551care. PLoS One. 2018 Nov 1;14(6).
- 13. Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for

- 553 implementation research: Conceptual distinctions, measurement challenges, and research 554 agenda. Adm Policy Ment Heal Ment Heal Serv Res. 2011 Mar;38(2):65–76.
- 55514.Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting556items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and557explanation. Vol. 349, BMJ (Online). BMJ Publishing Group; 2015.
- 55815.Wells G, Shea B, Robertson J, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale559(NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis.
- Fage MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020
 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews.
 Vol. 372, The BMJ. BMJ Publishing Group; 2021.
- 56317.Bulterys MA, Oyaro P, Brown E, Yongo N, Karauki E, Wagude J, et al. Costs of point-of-care viral564load testing for adults and children living with hiv in kenya. Diagnostics. 2021 Jan 1;11(1).
- Drain PK, Dorward J, Violette LR, Quame-Amaglo J, Thomas KK, Samsunder N, et al. Point-of-care
 HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM):
 findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV. 2020 Apr
 1;7(4):e229–37.
- 19. Nicholas S, Poulet E, Wolters L, Wapling J, Rakesh A, Amoros I, et al. Point-of-care viral load
 570 monitoring: outcomes from a decentralized HIV programme in Malawi. J Int AIDS Soc.
 571 2019;22(8):1–9.
- 57220.Rasti R, Nanjebe D, Karlström J, Muchunguzi C, Mwanga-Amumpaire J, Gantelius J, et al. Health573care workers' perceptions of point-of-care testing in a low-income country A qualitative study in574Southwestern Uganda. PLoS One. 2017 Jul 1;12(7).
- 575 21. Reif LK, Belizaire ME, Rouzier V, Seo G, Severe P, Bajo Joseph JM, et al. Point-of-care viral load
 576 testing among adolescents and young adults living with HIV in Haiti: a randomized control trial.
 577 AIDS Care Psychol Socio-Medical Asp AIDS/HIV. 2022;34(4):409–20.
- Sharma M, Mudimu E, Simeon K, Bershteyn A, Dorward J, Violette LR, et al. Cost-effectiveness of
 point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. Lancet HIV.
 2021 Apr 1;8(4):e216–24.
- Simeon K, Sharma M, Dorward J, Naidoo J, Dlamini N, Moodley P, et al. Comparative cost analysis
 of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South
 Africa. PLoS One. 2019 Oct 1;14(10).
- Vasconcellos I, Mariani D, Azevedo MCVM d., Ferreira OC, Tanuri A. Development and validation
 of a simple and rapid way to generate low volume of plasma to be used in point-of-care HIV virus
 load technologies. Brazilian J Infect Dis. 2020 Jan 1;24(1):30–3.
- 587 25. Villa G, Abdullahi A, Owusu D, Smith C, Azumah M, Sayeed L, et al. Determining virological
 588 suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub589 Saharan Africa. EClinicalMedicine. 2020 Jan 1;18.
- Wang M, Boeke CE, Rioja MR, Maparo T, Banda C, Chavula C, et al. Feasibility and impact of nearpoint-of-care integrated tuberculosis/HIV testing in Malawi and Zimbabwe. AIDS. 2021 Dec
 1;35(15):2531–7.

593 27. Broucker G De, Salvatore PP, Mutembo S, Moyo N, Mutanga JN, Thuma PE, et al. The cost594 effectiveness of scaling-up rapid point-of-care testing for early infant diagnosis of HIV in southern
595 Zambia. PLoS One. 2021 Mar 1;16(3 March).

- 59628.de Necker M, de Beer JC, Stander MP, Connell CD, Mwai D. Economic and public health impact of597decentralized HIV viral load testing: A modelling study in Kenya. PLoS One. 2019 Feb 1;14(2).
- 59829.Engel N, Davids M, Blankvoort N, Pai NP, Dheda K, Pai M. Compounding diagnostic delays: A599qualitative study of point-of-care testing in South Africa. Trop Med Int Heal. 2015 Apr6001;20(4):493-500.
- Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S. Optimizing viral load
 testing access for the last mile: Geospatial cost model for point of care instrument placement.
 PLoS One. 2019 Aug 1;14(8).
- 60431.Girdwood SJ, Crompton T, Sharma M, Dorward J, Garrett N, Drain PK, et al. Cost-effectiveness of605adoption strategies for point of care HIV viral load monitoring in South Africa. EClinicalMedicine.6062020 Nov 1;28.
- 60732.Boeke CE, Joseph J, Atem C, Banda C, Coulibaly KD, Doi N, et al. Evaluation of near point-of-care608viral load implementation in public health facilities across seven countries in sub-Saharan Africa.6092021; Available from: http://onlinelibrary.wiley.com/doi/10.1002/jia2.25663/full
- Tembo T, Dale H, Muttau N, Itoh M, Williamson D, Mwamba C, et al. "Testing Can Be Done
 Anywhere": A Qualitative Assessment of Targeted Community-Based Point-of-Care Early Infant
 Diagnosis of HIV in Lusaka, Zambia [Internet]. 2022. Available from: www.ghspjournal.org
- 61334.Boyce RM, Ndizeye R, Ngelese H, Baguma E, Shem B, Rubinstein RJ, et al. It takes more than a614machine: A pilot feasibility study of point-of-care HIV-1 viral load testing at a lower-level health615center in rural western Uganda. PLOS Glob Public Heal. 2023 Mar 1;3(3).
- 616 35. Engel N, Davids M, Blankvoort N, Dheda K, Pant Pai N, Pai M. Making HIV testing work at the
 617 point of care in South Africa: A qualitative study of diagnostic practices. BMC Health Serv Res.
 618 2017;17(1).
- 619 36. Estill J, Egger M, Blaser N, Vizcaya LS, Garone D, Wood R, et al. Cost-effectiveness of point-of-care
 620 viral load monitoring of antiretroviral therapy in resource-limited settings: Mathematical
 621 modelling study. AIDS. 2013 Jun 1;27(9):1483–92.
- 62237.Ganesh P, Heller T, Chione B, Gumulira J, Gugsa S, Khan S, et al. Near Point-of-Care HIV Viral623Load: Targeted Testing at Large Facilities [Internet]. 2020. Available from: www.jaids.com
- 62438.Gueguen M, Nicholas S, Poulet E, Schramm B, Szumilin E, Wolters L, et al. Implementation and625operational feasibility of SAMBA I HIV-1 semi-quantitative viral load testing at the point-of-care in626rural settings in Malawi and Uganda. Trop Med Int Heal. 2021 Feb 1;26(2):184–94.
- Kufa T, Mazanderani AH, Sherman GG, Elie Mukendi A, Murray T, Moyo F, et al. Point-of-care HIV
 maternal viral load and early infant diagnosis testing around time of delivery at tertiary obstetric
 units in South Africa: a prospective study of coverage, results return and turn-around times. J Int
 AIDS Soc 2020, 23e25487 [Internet]. 2020; Available from:
- 631 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25487/full
- 40. Msimango L, Gibbs A, Shozi H, Ngobese H, Humphries H, Drain PK, et al. Acceptability of point-of-

- care viral load testing to facilitate differentiated care: a qualitative assessment of people living
 with HIV and nurses in South Africa. BMC Health Serv Res. 2020 Dec 1;20(1).
- 41. Ndlovu Z, Fajardo E, Mbofana E, Maparo T, Garone D, Metcalf C, et al. Multidisease testing for
 HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe. PLoS One. 2018
 Mar 1;13(3).
- 638

639

- 640 **Supporting information**
- 641 S1 Figure PRISMA Diagram
- 642 S1 Table Search Strategy
- 643 S2 Table PRISMA checklists
- 644 S3 Table Reasons for exclusions
- 645 S4 Table Newcastle Ottawa Scale
- 646
- 647
- 648 649

650 Authors' contributions

PM performed the literature search, screening, data extraction and analysis and constructed the manuscript. MS performed the literature search, screening, data extraction and data analysis, review of articles, corrected the manuscript, IS reviewed the study results and final draft, KN reviewed the introduction and final draft. RR reviewed and corrected the manuscript. AL performed the literature search, screening, data extraction and data analysis. AH corrected the final manuscript. BM reviewed and corrected the final draft.




Figure 1: PRISMA diagram of studies screening and selection